TECHWIRE 30
(CIX: WRAL30)  990.01  up arrow+0.9  (0.09 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Apple)  519.01  up arrow+1.05  (0.2 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: QUINTILES)  50.60    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: BASF SE)  108.14    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: BioCryst)  8.34    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: BioDelivery)  7.40    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: CEMP)  9.23    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Cisco Systems)  23.03    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  56.38    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: DARA)  2.48    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: EMC CORPORATION)  26.70    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Extreme Networks)  5.62    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Facebook)  59.72  up arrow+0.63  (1.07 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: GLAXOSMITHKLINE)  52.82    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: GOOG)  556.54    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: IBM)  196.40    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NY: LH)  101.95    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: Lenovo Group)  24.14    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: MRK)  56.26    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Microsoft Corp)  40.40    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: NetApp)  36.24    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: NOVARTIS AG)  84.41    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(OP: Novozymes A/S)  44.91    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: PFIZER)  30.09    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: Pozen)  8.73    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NY: RED HAT)  50.62    (0 %)  Updated: 06:40 PM EDT, Apr 16 2014
(NQ: BBRY)  7.15    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: Salix)  100.66    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014
(NQ: SQI)  26.00    (0 %)  Updated: 08:10 PM EDT, Apr 16 2014

Posts tagged “Salix”

Updated July 31, 2012

Premium Lock Salix delays big hiring plans after FDA rejects drug

Salix Salix will no longer add an additional 160 primary-care sales representatives later this year and plans to update its 2012 earnings forecast when it releases second-quarter results on Aug. 8.

July 30, 2012

Premium Lock In the news: Quintiles, Salix, Furiex, AAD

Bulldog Inside the Bulldog Blog: Quintiles lands drug promotion deal; Salix seeks FDA meeting about drug response; Furiex resubmits diabetes drug; Advanced Animal Diagnostics adds two execs.

May 8, 2012

Premium Lock Salix revenue rises 62% in first quarter, beats Street

Salix Salix Pharmaceuticals announced on Monday a 62 percent increase in its first quarter revenue for 2012 with total product revenue at $171.1 million thanks in part to the company's leading drug Xifaxan.

Tags: Salix
May 1, 2012

Premium Lock FDA delays decision on Salix drug to treat HIV-related diarrhea

HIV research Salix had been scheduled for a June 5 decision date on its experimental diarrhea treatment crofelemer. But the Raleigh company says FDA regulators need more time to review the submission.

April 26, 2012

Premium Lock FDA oushes back review for Salix constipation treatment

Salix An approval decision was expected on April 27. But the U.S. Food and Drug Administration has notified the Raleigh-based company that it needs more time. The new target date to issue an approval decision is July 27.

March 13, 2012

Premium Lock Raleigh-based Salix Pharmaceuticals to raise $600M

Salix Salix says it will repurchase outstanding convertible senior notes that are due in 2028. The company also plans to repurchase up to $75 million of its outstanding common stock and will also use proceeds for corporate purposes.

February 28, 2012

Premium Lock How long before Salix Pharmaceuticals hits $1B?

Salix After a 60 percent jump in revenue in 2011 to $540 million, the Raleigh-based drug firm forecasts a 36 percent jump in 2012 to $735 million.

February 22, 2012

Premium Lock In the news: Visilink's LED wireless; MercuryGate grows; Salix drug trial; Furiex cuts losses; iContact donations; Software Toolbox update

Tech briefs Local tech briefs: Cary-based Visilink unveils LED-based wireless; Cary firm MercuryGate expands to Asia; Salix launches new drug trial; Furiex cuts its losses; iContact donates $200,000; Charlotte firm updates automation software.

Updated February 7, 2012

Premium Lock Salix drug receives priority FDA review, but partner wants it back

Salix The Raleigh firm is tied up in a law suit over the development of the drug that's intended to help AIDS patients suffering with diarrhea.

December 21, 2011

Premium Lock Salix's pill version of Relistor succeeds in phase 3; NDA expected in 2012

Salix Salix released successful phase 3 clinical trial results for the oral version of Relistor and now plans to submit a new drug application for the compound in the middle of 2012.

November 15, 2011

Premium Lock Salix faces tough questions from FDA about expanded use of drug

Salix Salix is preparing for new set of Xifaxan phase 3 clinical trials studying the irritable bowel syndrome indication, which puts approval about two years away. But first the company will meet with an FDA advisory panel on Wednesday, eight months after receiving the complete response letter from the agency declining approval on Xifaxan as a new IBS treatment.

Updated November 15, 2011

Premium Lock FDA raises questions about Salix drug; shares fall 10%

Salix Triangle-based Salix wants to expand use of its bowel drug but the FDA raised questions that concern an analyst who follows the company.

November 11, 2011

Premium Lock California drug firm terminates potential blockbuster deal with Salix

Salix "Napo believes Salix has materially breached the collaboration agreement by unnecessarily stalling the advancement of this compound," Napo Pharmaceuticals says. "Most notably, Salix has failed to file an NDA one year after a highly successful phase 3 clinical trial or to prepare for commercial manufacture of the drug -- critical tasks that were fundamental to its responsibilities."

November 9, 2011

Premium Lock Salix acquires NJ pharma firm for $300M; earnings soar

Salix "The acquisition of Oceana expands our product portfolio of innovative products, furthers the diversification of Salix's base business and provides immediate added revenue," says Salix CEO Carolyn Logan.

August 31, 2011

Premium Lock FDA to consider additional use for Salix drug

Salix Salix and drug partner Progenics Pharmaceuticals want to expand Relistor's use to treat opioid-induded constipation in patients taking the drugs for non-cancer pain.

August 9, 2011

Premium Lock Salix faces a delay in OK for wider use of drug

Salix Data from proposed irritable bowel syndrome drug Xifaxan faces further review, Salix says. The FDA rejected Xifaxan as IBS tgreatment in March.

May 9, 2011

Premium Lock Salix faces suit from drug development partner

Salix The Raleigh-based company says that the suit's charges "are without merit."

April 20, 2011

Premium Lock Salix wins more patent coverage of diarrhea drug

Salix The Raleigh-based company expects Xifaxan sales to top $300 million this year.

March 1, 2011

Premium Lock Salix profit tops Street estimates, but revenue, forecast miss

Salix The Raleigh-based pharmaceutical firm, whose stock was rocked last week by at FDA delay, reports sharp increase in profits and revenues from fourth quarter a year ago.

Updated February 25, 2011

Premium Lock FDA delay sends Salix shares plunging 23%

Salix The Raleigh-based pharmaceutical firm says the FDA wants more information about possible expanded use of a drug to treat non-constipation irritable bowel syndrome.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Frank Vinluan
Life science
Dr. Mike Walden
Tech economy
Vivek Wadhwa
Commentary
Scroll